<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581109</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0318</org_study_id>
    <secondary_id>2018-A03249-46</secondary_id>
    <nct_id>NCT04581109</nct_id>
  </id_info>
  <brief_title>Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)</brief_title>
  <acronym>EPIDROP</acronym>
  <official_title>Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of liquid biopsy could be the key for precision medicine. Circulating tumor cells&#xD;
      (CTCs) are the most studied circulating biomarkers used to assess the metastatic process and&#xD;
      they have shown their clinical validity and utility in cancer patients. However, their&#xD;
      detection and capture are still a challenge as they are very rare in the bloodstream. In this&#xD;
      clinical trial named &quot;EPIDROP&quot;, the investigators will use an innovative device called&#xD;
      EPIDROP (for EPIspot in a DROP) in metastatic prostate cancer. EPIDROP is a completely new&#xD;
      technology answering to biological and clinical questions by proposing a procedure detecting&#xD;
      the functional subset of prostatic CTCs at the single cell level. The investigators will&#xD;
      stain cells in the sample for EpCAM, PSMA, CD45 before to encapsulate them one by one in&#xD;
      microdroplets and measure the PSA secretion by only the viable CTCs. This study aims to&#xD;
      demonstrate the non-inferiority of the EPIDROP compared to the CellSearch system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods :&#xD;
&#xD;
      One hundred patients with a metastatic prostate cancer will be recruited plus 50 healthy&#xD;
      donors. Twenty ml of blood will be drawn : 10 ml of blood will be drawn on CellSave tubes&#xD;
      (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and&#xD;
      10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional&#xD;
      CTCs using the EPIDROP. Patients will be followed for 18 months.&#xD;
&#xD;
      Samples from fifty control subjects will be provided by the Etablissement Français du Sang.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EPIDROP technique sensitivity versus CellSearch system sensitivity</measure>
    <time_frame>At 18 months</time_frame>
    <description>Proportion of true positive and false negative patients with a confidence interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EPIDROP technique specificity versus CellSearch system specificity</measure>
    <time_frame>At 18 months</time_frame>
    <description>Proportion of true negative and false positive healthy controls with a confidence interval</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.</description>
    <arm_group_label>Patients with metastatic prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  To be male, over 18 years old&#xD;
&#xD;
          -  Metastatic prostate cancer naive to any treatment or metastatic prostate cancer in&#xD;
             biological recurrence (PSA increase) and/or clinical recurrence after hormone&#xD;
             suppression (mCRPC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-metastatic prostate cancer in biological and/or clinical recurrence after&#xD;
             hormone-suppression (nmCRPC)&#xD;
&#xD;
          -  Other active or treated cancer less than 5 years old&#xD;
&#xD;
          -  Be protected by law (guardianship or curatorship)&#xD;
&#xD;
          -  Be deprived of liberty by administrative decision&#xD;
&#xD;
          -  Not being affiliated to a social security scheme, or not being a beneficiary of such a&#xD;
             plan&#xD;
&#xD;
          -  Being in a period of exclusion from another protocol&#xD;
&#xD;
          -  Inability to understand and/or respond to questionnaires&#xD;
&#xD;
          -  Inability to understand the nature, purpose and methodology of the study&#xD;
&#xD;
          -  Refusal to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine ALIX-PANABIERES, MCU-PH</last_name>
    <phone>04 11 75 99 31</phone>
    <phone_ext>+33</phone_ext>
    <email>c-panabieres@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Center</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Center, Hospital</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane DROUPY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumor cells (CTCs)</keyword>
  <keyword>Biomarker</keyword>
  <keyword>CellSearch</keyword>
  <keyword>EPIDROP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

